Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +55

Gilead Sciences stock falls 1.11 percent despite revenue growth

Dividend Earnings report AI-generated analysis

πŸ“ˆ Gilead Sciences reported Q2 2026 revenue of USD 7.80 billion, up 10 percent year-over-year and above the Zacks consensus estimate of USD 7.37 billion.

πŸ’Š HIV product sales surged 12 percent to USD 5.69 billion, serving as the primary driver for overall revenue growth in the quarter.

πŸ“‰ Cell-therapy sales declined 14 percent to USD 417 million, contributing to a reported adjusted loss of USD 6.75 per share.

🎯 The company maintained its full-year 2026 product-sales guidance range of USD 30.10 billion to USD 30.40 billion despite the acquisition-related charges.

πŸ“ˆ HSBC raised its price target to USD 175 from USD 155 and maintained a Buy rating following the earnings release.

πŸ’° Gilead declared a quarterly dividend of USD 0.82 per share payable on September 29, 2026.

πŸ“Š The stock traded at USD 149.69 on September 24, 2026, down 1.11 percent despite the positive revenue beat.

πŸš€ Gilead lifted its HIV sales-growth outlook to 9-10 percent from the previous 8 percent forecast.

Bullish Signals
  • Gilead Sciences achieved Q2 revenue of USD 7.80 billion, beating analyst estimates and demonstrating strong top-line growth driven by a 12% increase in HIV sales.
  • The company maintained its full-year 2026 product-sales guidance between USD 30.10 billion and USD 30.40 billion, indicating stable long-term expectations.
  • HSBC raised its price target to USD 175 from USD 155 and reaffirmed a Buy rating, reflecting strong institutional confidence in the stock.
  • Gilead increased its HIV sales-growth outlook to 9-10 percent, showing management's optimism for its core franchise performance.
  • The reported adjusted loss was narrower than expected at USD 6.75 versus a consensus loss of USD 7.07, mitigating downside risk.
Risk Factors
  • Cell-therapy sales fell 14 percent to USD 417 million in the second quarter, highlighting weakness in the company's emerging biotech portfolio.
  • The reported adjusted earnings per share were a loss of USD 6.75 due to significant acquisition-related in-process research and development expenses.
  • Despite revenue growth, Gilead Sciences stock fell 1.11 percent to close at USD 149.69, suggesting investors are pricing in the near-term earnings volatility.
Full Analysis
Gilead Sciences reported second-quarter 2026 revenue of USD 7.80 billion, representing a 10 percent increase from the prior-year quarter and surpassing analyst consensus estimates. This growth was driven primarily by HIV product sales, which rose 12 percent to USD 5.69 billion, while cell-therapy sales declined 14 percent to USD 417 million. Despite the top-line revenue expansion, Gilead's reported adjusted earnings per share fell to a loss of USD 6.75, which was narrower than the consensus expectation of a USD 7.07 loss. The company attributed this volatility largely to acquisition-related in-process research and development expenses incurred during the quarter. Looking ahead, Gilead maintained its full-year 2026 product-sales guidance between USD 30.10 billion and USD 30.40 billion. Additionally, the company lifted its HIV sales-growth outlook to a range of 9 percent to 10 percent, signaling continued confidence in its core franchise despite recent stock price weakness. Analyst sentiment remains positive with HSBC raising its price target to USD 175 and maintaining a Buy rating, while MarketBeat reports a Moderate Buy consensus. The company also declared a quarterly dividend of USD 0.82 per share payable on September 29, 2026.